ICER news on Analytics tool and roxadustat
- PDF / 169,240 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 208 Views
1
ICER news on Analytics tool and roxadustat The US Institute for Clinical and Economic Review (ICER) has launched ICER Analytics, to accelerate the application of ICER reports and assist payers, life science companies, patient groups and healthcare policy makers when developing drug formularies, negotiating drug prices, and investigating ways to apply evidence in order to create a healthcare system with fair prices and fair access for all patients.1 "Not only will ICER Analytics help people search and sort through our reports, but it will also make everything that we do more customizable and actionable. Those who want to insert their own evidence; who want to use the backbone of an ICER economic model to make a customized argument for value with a client or a negotiating partner; who want to compare quickly their own prices to the prices at different cost-effectiveness thresholds or using alternative measures to the QALY — all will find this now possible," said Dr Steven Pearson, the President of ICER. ICER reports will remain in the public domain as downloadable PDFs from the website. ICER Analytics is comprised of two tools: the ICER Evidence Compendium, a rapidly searchable and sortable summary of results from ICER reports with clinical effectiveness ratings and price benchmarks for each drug and indication, which will allow users to enter their own pricing to compare to ICER price benchmarks; and the ICER Interactive Modeler, providing access to ICER’s economic models, which will be customisable by the end user and allow companies to enter their own cost-effectiveness findings into the ICER Evidence Compendium. ICER will host a webinar on 17 December 2020 with payer and pharmaceutical industry representatives to demonstrate the Analytics tools and discuss their potential uses. ICER and the National Health Council (NHC) are launching a pilot program that will enable patient organisations belonging to the NHC’s voluntary health agency membership to access ICER Analytics for free. Non-NHC members will be granted access on a case-by-case basis. All HTA organizations from low- or middle-income countries will have free access, and subscription prices for other stakeholders will be scaled based on organisation type and size.
Roxadustat ICER has released a Draft Evidence Report on the effectiveness and value of roxadustat [AstraZeneca] for the treatment of anaemia in patients with chronic kidney disease (CKD).2 Roxadustat is currently under review by the US FDA, and a decision is expected in December 2020. Evidence from phase III trials found that roxadustat reduces the need for transfusion compared with placebo in patients with dialysis-independent CKD (DI-CKD), and reduces the need for IV iron supplementation in patients with dialysis-dependent CKD (DD-CKD). There was insufficient evidence to determine the impact of roxadustat on the risk of major adverse cardiac events (MACE) compared with erythropoietin-stimulating agents (ESAs; darbepoetin-alfa and epoetin-alfa). In economic modelling, the assumed placeholder p
Data Loading...
